The relationships between exogenous and endogenous antioxidants with the lipid profile and oxidative damage in hemodialysis patients

Miguel Roehrs¹, Juliana Valentini¹, Clóvis Paniz¹, Angela Moro¹,², Mariele Charão¹,², Rachel Bulcão¹,², Fernando Freitas¹,², Natália Brucker¹,², Marta Duarte¹, Mirna Leal³, Geni Burg¹, Tilman Grune⁴ and Solange Cristina Garcia¹*

Abstract

Background: We sought to investigate the relationships among the plasma levels of carotenoids, tocopherols, endogenous antioxidants, oxidative damage and lipid profiles and their possible effects on the cardiovascular risk associated with hemodialysis (HD) patients.

Methods: The study groups were divided into HD and healthy subjects. Plasma carotenoid, tocopherol and malondialdehyde (MDA) levels, as well as erythrocyte reduced glutathione (GSH), were measured by HPLC. Blood antioxidant enzymes, kidney function biomarkers and the lipid profiles were analyzed by spectrophotometric methods.

Results: Plasma lycopene levels and blood glutathione peroxidase (GPx) activity were significantly decreased in HD patients compared with healthy subjects. Total cholesterol, low-density lipoprotein cholesterol (LDL-c), creatinine, urea, MDA, GSH, superoxide dismutase (SOD) and catalase (CAT) were significantly increased in HD (p < 0.05). Lycopene levels were correlated with MDA (r = -0.50; p < 0.01), LDL-c (r = -0.38; p = 0.01) levels, the LDL-c/HDL-c index (r = -0.33; p = 0.03) and GPx activity (r = 0.30; p = 0.03). Regression models showed that lycopene levels were correlated with LDL-c (β estimated = -31.59; p = 0.04), while gender was correlated with the TC/HDL-c index and triglycerides. Age did not present a correlation with the parameters evaluated. GPx activity was negatively correlated with MDA levels and with the LDL-c/HDL-c and CT/HDL-c indexes.

Conclusions: Lycopene may represent an additional factor that contributes to reduced lipid peroxidation and atherogenesis in hemodialysis patients.

Background

In chronic renal failure (CRF) patients undergoing hemodialysis (HD) treatment, the formation of reactive oxygen species (ROS) is amplified, and oxidative stress may be one of the most relevant complications [1]. The increase in ROS is due to uremic toxins, bio-incompatible dialysate water, non-sterile dialysate, poor quality of dialysis water, back-leak of contaminants across the dialysis membrane and time of hemodialysis treatment [2,3].

In hemodialysis patients (HD), the major cause of death is cardiovascular disease, which is responsible for 50% of the mortality in this population [4,5]. The physiopathology of cardiovascular events in HD is multifactorial, but accelerated atherosclerosis seems to play a central role in cardiovascular dysfunction. In addition, current evidence suggests that the high prevalence of cardiovascular events in these patients is directly linked to oxidative stress and to the abnormality of the plasma lipid profile [6-10]. The abnormalities in the antioxidant defense system and increased oxidative stress may lead to higher susceptibility to lipid peroxidation of low density lipoprotein (LDL) [2,3,11]. Antioxidant vitamins and dietary constituents (for example, vitamin C, tocopherols, α-carotene...
and other carotenoids) may play an important role in protection against oxidative damage and, consequently, against atherosclerosis [12-14].

Although there are published studies that have evaluated biochemical alterations, endogenous antioxidants and vitamins in HD patients [15], there is lack of information about the relationships among oxidative stress biomarkers, vitamins and classical biochemical alterations. Therefore, the aim of this cross-sectional study was to evaluate whether exogenous and/or endogenous antioxidants may affect lipid peroxidation, cholesterol or cholesterol lipoproteins, which are important biomarkers involved in atherosclerosis in HD patients. Exogenous antioxidants, such as carotenoids (lycopene, lutein, zeaxanthin, α- and β-carotene, β-cryptoxanthin), vitamin E (α- and γ-tocopherol), and endogenous antioxidants (GSH, SOD, GPx and CAT), along with the serum lipid profile, lipid peroxidation biomarkers, and markers of serum kidney function, were evaluated.

Methods

Subjects
The study was approved by the Human Ethics Committee of the Science Health Center of the Federal University of Santa Maria (protocol number 091/2003). All patients gave their informed consent prior to inclusion in the study. The study included twenty-nine patients diagnosed with CRF (19 men and 10 women) and submitted to regular hemodialysis treatment at Charity and Health House Hospitals. Additionally, 20 healthy subjects, including 10 men and 10 woman (control group), were enrolled. In order to participate in this research, patients were required to have been receiving regular hemodialysis treatment. Only non-smokers who were free of any problems related to alcoholism, viral hepatitis and HIV were included in the study. Patients using any antioxidant vitamin within the last three months were also excluded. The control group did not have clinical histories of renal diseases or other pathologies. None of the healthy subjects received vitamins. The subjects were all non-smokers and did not consume alcohol regularly.

For the sampling, 10 ml of venous blood was collected from the HD patients before the hemodialysis process (two days after the last process) under conditions of fasting. Blood was also collected from the subjects in the control group. The analysis samples were divided into heparinized tubes, EDTA-containing tubes, and tubes without anticoagulant. Plasma-EDTA and serum were obtained by centrifugation at 1500 g for 10 minutes at 4°C. The plasma samples were used to evaluate carotenoids and tocopherols. To assess the antioxidant enzymes, blood samples were stored at -20°C until analysis. Plasma malondialdehyde (MDA) and erythrocyte reduced glutathione (GSH) were processed immediately followed by the determination of hemoglobin (Hb) levels and hematocrit (Hct) in the blood, as well as albumin, iron, ferritin, cholesterol, triglycerides, urea and creatinine levels in the serum.

The quantification of plasma carotenoids (lutein, zeaxanthin, lycopene, β-cryptoxanthin, α- and β-carotene) and tocopherols (α and δ-tocopherol) was carried out after liquid-liquid extraction with a solution of n-butanol:ethanol (50:50) in BHT (2,6-di-ter-butyl-4-methylphenol) mixed by vortexing and followed by centrifugation. The supernatant was analyzed by high performance liquid chromatography (HPLC) with a UV/VIS and fluorescent detector according to Epler et al., 1993 [16] with modifications. The β-apo-8 carotene was used as an internal standard.

Hemoglobin levels and hematocrit were determined in a Cobas Micros system (Hematology Analyzer, Roche Diagnostics®). The biochemistry analyses consisted of albumin, iron, ferritin, serum total cholesterol (TC), lower-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), triglycerides, urea and creatinine, which were determined using the Cobas Integra 400 (Roche Diagnostics®) automatic device and commercial kits. The indexes of coronary risk were obtained through the following calculations: TC/HDL-c and LDL-c/HDL-c.

Lipid peroxidation was estimated by the measurement of plasmatic malondialdehyde, which was determined by a high performance liquid chromatography with visible detection (HPLC-VIS) by Knauer® using a method developed in our laboratory [17].

The levels of reduced glutathione in erythrocytes were measured by high performance liquid chromatography with the Knauer® system using a method developed in our laboratory [18].

Enzyme assays were performed in total blood with heparin. Superoxide dismutase (SOD) activity was determined at 480 nm based on its ability to inhibit the autoxidation of adrenaline into adrenochrome at an alkaline pH [19]. Catalase (CAT) activity was determined at 280 nm using H₂O₂ as substrate [20]. Glutathione peroxidase (GPx) activity was determined using glutathione reductase and NADPH. The method is based on the oxidation of NADPH, which is measured by a decrease in absorbance at 340 nm [21]. These activities were measured spectrophotometrically using a UV-VIS model Hitachi U-1800®.

Statistical analysis
Statistical computations were performed with the Statistics® 6.0 software system (Statsoft Inc., 2001). The results are expressed as the mean ± SEM (standard error of the mean). Comparisons between groups were achieved by Student’s t-test or the Mann-Whitney test depending on the distribution of the variables. Pearson’s or Spearman’s
Results

The mean length of hemodialysis treatment in the HD patient group was 45.68 ± 7.27 months. The age of the HD patients was significantly higher than that of the control group’s patients (51.0 ± 2.17 and 43.15 ± 1.30 years (SEM), respectively). However, after regression analysis (Table 1), it was found that age did not have a significant influence on the parameters evaluated.

The clinical histories of the HD patients were evaluated, and the causes of renal failure were pyelonephritis and glomerulonephritis (n = 6 or 17.2% of the patients), hypertension (n = 3 or 10.3% of the patients), diabetes (n = 3 or 10.3% of the patients), polycystic kidney disease (n = 1 or 3.5% of the patients), tuberculosis of the urinary tract (n = 2 or 7% of the patients), and, in 37.9% of the patients (n = 11), there was no known cause.

With respect to the therapeutic treatment of the HD patients, it was observed that just six patients received vitamin D, while seventeen patients received erythropoietin, and eleven of those patients also received noripurum (saccharate ferric hydroxide). Moreover, statins were used for reducing lipid levels, and none of the patients received nutritional supplementation or a multivitamin complex. The treatments were chosen and changed by clinicians based on constant monitoring of the laboratorial results and clinical observations.

Serum levels of iron and ferritin in HD patients were 53.04 ± 3.69 mg.dL⁻¹ and 347.84 ± 72.40 ng.mL⁻¹ (SEM), respectively. These values were consistent with the reference values. Additionally, other hematological and biochemical analyses were performed monthly, and the results are presented in Tables 2 and 3 (reference values are also presented). Hematocrit, hemoglobin levels and albumin levels were lower in HD patients than in the control group, and they were below of the reference values. Biomarkers of renal function, including creatinine and urea, were significantly higher in HD patients and were above the reference values. Moreover, correlations between serum creatinine levels and GPx activity (r = -0.67; p < 0.01), as well as serum urea levels and GPx activity (r = -0.77; p < 0.01), were found.

The analysis of the lipid profile included total cholesterol (TC), LDL-c, HDL-c, triglycerides and the indexes of coronary risk (ICR), and the results are presented in the Table 3. The results are sub-grouped by gender within each group of study. In the control group, no difference was observed among the lipid profiles when comparing women vs. men. In the HD group, the triglycerides were significantly higher in men compared to women.

The levels of total cholesterol, LDL-c and triglycerides are within the reference values for both groups studied. However, the Mann-Whitney test revealed that these variables were significantly higher in the HD group compared with the control group. On the other hand, the HDL-c was below the reference values in HD patients, and it was also significantly decreased compared with the control group. The TC/HDL-c index was twice higher in HD compared to healthy subjects, and the LDL-c/HDL-c index was three times higher. Moreover, in the regression analysis, it was found that gender presented an influence on the TC/HDL index (β estimated = 1.05; p = 0.04) and triglyceride levels (β estimated = 17.82; p = 0.03).

Additionally, the clinical history of the HD group was evaluated for two years after the collection of the blood samples. Seven deaths occurred (24.1% of the total) in this period, and cardiovascular diseases (n = 6; 85.7%) was the main cause of death; only one of these deaths (3.5%) was due to a stroke. However, the Mann-Whitney test did not show statistically significant differences among any of the parameters analyzed between the HD patients that died (n = 7) during the present study and those that survived (n = 22). This lack of significant difference may be related to the small number of individuals in the group that died during the study.

The results of our analyses of the oxidative stress biomarkers are presented in Table 4. The plasma MDA and erythrocyte GSH levels were significantly increased in the HD patients compared to healthy subjects (p < 0.01).

The blood SOD and CAT activities were significantly increased (p < 0.05), while GPx activity was significantly decreased (p < 0.01) in HD patients compared with the control group. Moreover, in the control group, SOD, CAT and GPx activities were similar between women and men. On the other hand, the CAT activity was influenced by gender in the HD group, as it was higher in women than men. The results of the Mann-Whitney test showed that gender had a significant effect on some of the parameters evaluated (Tables 2 to 5). However, only the TC/HDL-c index and triglyceride levels were influenced by gender in regression models (Table 1).

The non-enzymatic and enzymatic endogenous antioxidants listed above were linearly associated the hematocrit and hemoglobin levels, as well as urea and creatinine levels (data not shown). In addition to these correlations, the lipid profile also presented linear associations with endogenous antioxidants (p < 0.05). GSH was significantly associated
Table 1 Regression analysis realized to lipid peroxidation, lipid profile and antioxidants.

|             | LDL-c (R²) of model: 0.14 | HDL-c (R²) of model: 0.67 | MDA (R²) of model: 0.47 | TC/HDL (R²) of model: 0.53 | LDL/HDL (R²) of model: 0.60 | TG (R²) of model: 0.51 |
|-------------|-----------------------------|-----------------------------|--------------------------|-----------------------------|-----------------------------|--------------------------|
| β coeff     | p                           | β coeff                    | p                        | β coeff                    | p                           | β coeff                  |
| Age         | ns 0.75                     | ns 0.11                     | ns 0.10                   | ns 0.08                    | ns 0.33                     | ns 0.35                  |
| Gender      | ns 0.66                     | ns 0.11                     | ns 0.08                   | 1.05 0.04                  | ns 0.10                     | 17.82 0.03               |
| SOD         | ne -                        | ns 0.69                     | ns 0.45                   | ne -                       | ns 0.92                     | ns 0.29                  |
| CAT         | ne -                        | ns 0.48                     | ns 0.62                   | ns 0.70                    | ns 0.80                     | ns 0.64                  |
| GPx         | ne -                        | 3.39 0.003                  | - 0.33 0.02               | - 0.54 0.03                | - 0.55 0.001                | - 10.16 0.004            |
| GSH         | ns -                        | ns 0.66                     | ns 0.48                   | ns 0.48                    | ns 0.89                     | ns 0.38                  |
| Lycopene    | - 31.59                     | 0.044                       | ns 0.23                   | ns 0.75                    | ns 0.52                     | ns 0.20                  |
| Lutein      | ns 0.67                     | ns 0.60                     | ns 0.82                   | ns 0.51                    | ns 0.47                     | ns 0.63                  |

ns: non significant.
ne: non entered in this regression model.
(p < 0.05) with LDL-c (r = -0.38), HDL-c (r = -0.43), the LDL/HDL index (r = 0.47), the TC/HDL index (r = 0.41) and MDA (r = 0.54). SOD and CAT activities were correlated with HDL-c (r = -0.34 and -0.48), the LDL/HDL index (r = 0.31 and 0.42) and MDA (r = 0.49 and 0.45). In addition, CAT was positively associated with the TC/HDL index (r = 0.52). However, a positive association was observed between GPx activity and HDL (r = 0.64), and a negative association was observed between GPx activity and LDL-c (r = -0.64), the LDL/HDL index (r = -0.72), the TC/HDL index (r = -0.72) and MDA (r = -0.73).

The results of our analyses of carotenoids and total-tocopherols (T-tocopherols) are summarized in Table 5. There was no significant difference for lutein, zeaxanthin, cryptoxanthin or β-carotene levels between the HD group and the control group (p > 0.05). Moreover, both alpha-carotene and lycopene levels were reduced by half in the hemodialysis group compared with the control group (p < 0.05). Additionally, Spearman’s correlation showed that lycopene levels were negatively correlated with MDA levels (r = -0.50; p < 0.01), LDL-c (r = -0.38; p = 0.01) and the LDL-c/HDL-c index (r = -0.33; p = 0.03). Otherwise, this exogenous antioxidant was positively correlated with GPx activity (r = 0.30; p = 0.03). Furthermore, significant associations (p < 0.05) between lutein and LDL-c (r = -0.30), the LDL-c/HDL-c index (r = -0.33) and MDA levels (r = -0.45) were observed.

Regression models (Table 1) were performed based on the significant correlations obtained among exogenous and endogenous antioxidants and the lipid profile and the lipid peroxidation product (MDA). The total cholesterol and triglyceride levels were not associated with other biochemical parameters or with exogenous or endogenous antioxidants except GPx activity. Additionally, hematological and renal biomarkers were entered in these models as co-variables, and they did not influence

### Table 2 Hematological and biochemical analysis

| Parameters         | Healthy Subjects (n = 20) | Hemodialysis Patients (n = 29) | Reference Values57 |
|--------------------|---------------------------|-------------------------------|--------------------|
|                    | Men (n = 10) | Women (n = 10) | Men (n = 19) | Women (n = 10) | Men | Women |
| Hemoglobin (g.dL⁻¹) | 14.90 ± 0.50 | 9.92 ± 0.29<sup>c</sup> | 165 ± 0.4 | 128.0 ± 0.1 | 100 ± 0.04<sup>c</sup> | 9.7 ± 0.5<sup>c</sup> | 12 - 18 | 11 - 16 |
| Hematocrit (%)     | 43.20 ± 1.20 | 30.54 ± 4.73<sup>ab</sup> | 46.9 ± 0.8 | 38.0 ± 0.8 | 308 ± 12<sup>c</sup> | 298 ± 1.4<sup>c</sup> | 39 - 53 | 35 - 47 |
| Albumin (g.dL⁻¹)   | 3.98 ± 0.06 | 3.15 ± 0.03<sup>abc</sup> | 4.02 ± 0.1 | 3.9 ± 0.05 | 3.2 ± 0.03<sup>c</sup> | 3.1 ± 0.05<sup>c</sup> | 3.4 - 5.0 |
| Creatinine (mg. dL⁻¹) | 0.68 ± 0.07 | 10.17 ± 0.62<sup>ab</sup> | 0.89 ± 0.06 | 0.39 ± 0.03 | 11.5 ± 0.08 | 840 ± 0.83 | 0.8 - 1.3 |
| Urea (mg. dL⁻¹)    | 2740 ± 1.60 | 164.55 ± 7.64<sup>ab</sup> | 28.96 ± 2.55 | 25.29 ± 1.36 | 171.10 ± 10.10 | 160.21 ± 11.73 | 15 - 39 |

The values are expressed as mean ± standard error of the mean (SEM).

<sup>a</sup> p < 0.05 when compared with healthy subjects; <sup>b</sup> Inter gender difference (p < 0.05); <sup>c</sup> Below to reference value.

### Table 3 Lipid profile results of studied groups and reference values

| Parameters         | Healthy Subjects (n = 20) | Hemodialysis Patients (n = 29) | Reference Values57 |
|--------------------|---------------------------|-------------------------------|--------------------|
|                    | Men (n = 10) | Women (n = 10) | Men (n = 19) | Women (n = 10) | Men | Women |
| TC (mg.dL⁻¹)       | 147.27 ± 4.48 | 181.14 ± 5.36<sup>a</sup> | 145.9 ± 7.9 | 148.9 ± 4.1 | 178.2 ± 6.2 | 182.7 ± 10.3 | < 200 |
| LDL-c (mg.dL⁻¹)    | 72.66 ± 4.37 | 115.89 ± 3.79<sup>a</sup> | 69.4 ± 6.5 | 76.9 ± 5.6 | 117.5 ± 4.5 | 111.5 ± 7.0 | < 130 |
| HDL-c (mg.dL⁻¹)    | 55.90 ± 3.00 | 28.89 ± 1.92<sup>a</sup> | 53.0 ± 3.9 | 61.0 ± 3.9 | 29.2 ± 2.9 | 28.7 ± 2.4 | > 40 | > 45 |
| TG (mg.dL⁻¹)       | 90.70 ± 6.40 | 160.37 ± 9.28<sup>b</sup> | 90.7 ± 6.3 | 85.4 ± 11.0 | 175.4 ± 11.9 | 131.9 ± 11.7<sup>b</sup> | < 150 |
| LDL-c/HDL-c        | 1.28 ± 0.11 | 4.48 ± 0.32<sup>a</sup> | 1.3 ± 0.1 | 1.2 ± 0.2 | 4.7 ± 0.5 | 4.0 ± 0.2 | < 3.55 |
| TC/HDL-c           | 2.68 ± 0.15 | 7.12 ± 0.55<sup>a</sup> | 2.8 ± 0.2 | 2.5 ± 0.3 | 7.3 ± 0.9 | 6.8 ± 0.6<sup>b</sup> | < 5 |

The values are expressed as mean ± standard error of the mean (SEM).

<sup>a</sup> p < 0.05 when compared with healthy subjects; <sup>b</sup> Inter gender difference (p < 0.05).

Abbreviations: TC: cholesterol total; LDL-c: LDL cholesterol; HDL-c: HDL cholesterol; TG: triglycerides.
the interpretation of the models. The results showed that lycopene levels were inversely associated with the LDL-c and HDL-c levels and were positively associated with GPx activity. On the other hand, a negative association was found between GPx activity and MDA levels. Moreover, the GPx activity was a significant variable in the regression models for the TC/HDL-c and LDL-c/HDL-c indexes.

Discussion
Cardiovascular diseases play an important role in the mortality of HD patients, and we observed that all HD patient deaths that occurred during the study were due to vascular diseases. The pathogenesis of atherosclerotic ischemic heart disease resulted, in part, from the over-production of reactive species of oxygen and nitrogen. Furthermore, HD process is associated with impairment of the antioxidant defense mechanisms, which is one of the main factors that contributes to cardiovascular disease and is a significant cause of morbidity and mortality in these patients [22]. Therefore, it is of particular interest to explore the possible associations among oxidative stress biomarkers, exogenous antioxidants, such as vitamins, and, especially, the carotenoids, the lipid profile and the risk of cardiovascular disease in HD patients.

In the present study, HD patients showed a moderate increase in triglycerides and total and LDL cholesterol
association with antioxidant enzymes [33], is observed to be based on the positive relationship between this cholesterol fraction and GPx activity. However, the lower levels of HDL and GPx activity cannot counter the oxidative stress [34–37] or the increase in atherogenic indexes. Moreover, CAT and SOD activities were increased, as well as the GSH levels, to compensate for the oxidative stress that results from the hemodialysis process [30,38].

With respect to exogenous antioxidants, the antioxidant and anti-inflammatory activity [8] of vitamin E (α- and γ-tocopherol) is known, and the vitamin E deficiency in HD patients conflicts with previous results [39]. In this work, the plasma vitamin E levels were not reduced HD patients in comparison with controls, which is consistent with previous studies where blood collection was performed before hemodialysis treatment [40,41]. Moreover, the levels of vitamin E were not associated with their main function, which is to prevent lipid peroxidation and, consequently, to prevent LDL oxidation [42,43]. However, this lack of association could be due to the fact that we evaluated only MDA levels, and the specific LDL oxidation product was not quantified.

The majority of the previous studies evaluated the total carotenoids [44] or β-carotene [45]; in the present study, we investigated the individual carotenoids. It is known that carotenoids have an important role in the prevention of human diseases, such as cataracts, cancer and other diseases acting as antioxidants [38,46], as well as heart protection in hemodialysis patients [47]. Usually, dialysis patients have abnormal levels of vitamin and carotenoid because of inadequate dietary intake resulting from poor appetite, dietary restrictions and metabolic disorders associated with renal failure [47,48]. In this study, the HD patients only had lower levels of lycopene and α-carotene in comparison to controls. Several studies have indicated that lycopene is an effective antioxidant and a free radical scavenger because of the number of conjugated double bonds [46,49]. Lycopene has also been suggested as a possible carcinogenesis and atherogenesis prevention agent because it protects critical biomolecules, including lipids, low-density lipoproteins (LDL), proteins and DNA [50]. Our results are consistent with previous reports [30,51], which found that levels of lycopene are reduced almost by half in HD patients compared with healthy subjects. In 1994, Loughrey et al. [52] demonstrated that macrophage enrichment with lycopene or with α-carotene results in the suppression of cellular cholesterol synthesis and an increase in macrophage LDL receptor activity. This effect can lead to enhanced clearance of LDL from the plasma. In this line, the multivariate analysis conducted here demonstrated an inverse association of lycopene levels and LDL-c levels, suggesting that lycopene could be considered an important extrinsic factor for the prevention of atherosclerosis,
which is consistent with the findings of Rissanen et al., 2002 [53]. In addition to a probable protective effect of lycopene, these results demonstrated a lack of association with gender or age.

In the present study, we found that α-carotene levels were higher in the control group compared with healthy subjects in a Canadian study [51]. This could be due to interregional variations in diet. Levels of β-carotene, lutein, zeaxanthin and β-cryptoxanthin showed no significant differences between the studied groups. Levels of β-cryptoxanthin and β-carotene were consistent with those reported by Sundl et al. 2009 [51]. Moreover, an influence of gender on the levels of these carotenoids was also observed in another study, which reported that the values were higher in women than in men [54]. Interestingly, there are studies that report the existence of the reference values for different populations [55]. Our results are similar to those obtained in a Spanish population [56]; however, in this population, inter-gender variation was not observed. With respect to zeaxanthin and lutein levels, our results are consistent with those of previous reports [51,54].

Thus, our results demonstrated that GPx, an endogenous antioxidant with an important function in renal tissue, influenced lipid damage. Importantly, lycopene, an exogenous antioxidant, may modulate lipid profile disturbance and, potentially, be protective against atherosclerosis in HD patients. Subject age did not influence the evaluated indexes of cardiovascular risk or the markers of oxidative stress and vitamins. However, gender was found to influence triglycerides and the total cholesterol/HDL-c index.

Conclusions
We showed that hemodialysis patients had reduced levels of lycopene and GPx enzyme activity which were associated with an increase in lipid damage that was evident based on increased lipid peroxidation and decreased HDL-c levels. It was demonstrated that the HD patients have higher index values for atherogenic risk. Thus, the decline of important exogenous (lycopene) and endogenous (GPx activity) antioxidants associated with the lipid profile could directly influence morbidity and mortality in these patients. However, more studies are required to verify whether it is possible to increase lycopene levels through diet, and the likely role of decreased GPx activity in cardiac risk and atherogenesis in this group of patients should be further investigated.

Acknowledgements
The authors would like to thank Capes/DAAD for supporting Prof Dr. S.C. Garcia’s scientific visit to Germany (Institute of Biological Chemistry and Nutrition). We would also like to thank Michael Wolter from the Institute of Biological Chemistry and Nutrition (Germany) for assisting in the quantification of plasma carotenoid levels. S.C. Garcia has received a CNPq researcher fellowship.

Author details
1Laboratory of Toxicology (LATOX), Department of Clinical and Toxicology, Faculty of Pharmacy, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil. 2Post-graduate Program in Pharmaceutical Sciences, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil. 3Department of Physiology, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil. 4Institute of Nutrition, Friedrich Schiller University Jena, Jena, Germany.

Authors’ contributions
The authors MR, JP, AM, MC, RB, NB, FA, MD, ML have made substantial contributions to the conception and design of the study, the acquisition of data and the analysis and interpretation of data, and the authors TG and SG participated in drafting the manuscript or critically revising it for important intellectual content. The authors have also given final approval of the version to be published. Each author has participated sufficiently in the work to take public responsibility for appropriate sections of the content.

Competing interests
The authors declare that they have no competing interests.

Received: 1 February 2011 Accepted: 26 October 2011
Published: 26 October 2011

References
1. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Warner C. Inflammation enhances cardiovascular risk and mortality in haemodialysis patients. Kidney Inter 1999, 55:648-58.
2. Morena M, Cristol JP, Canaud B. Why haemodialysis patients are in a prooxidant state? What could be done to correct the pro/antioxidant imbalance. Blood Purif 2000, 18:191-99.
3. Nguyen-Khoa T, Massy ZA, De Bandt JP, Kebiede M, Salama L, Lambrey G, Witko-Sarast V, Druelke TB, Lacour B, Thvenin M. Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant 2001, 16:335-40.
4. Port F. Mortality and causes of death in patients with end-stage renal failure. Am J Kidney Dis 1990, 15:215-17.
5. Panfrey PS, Hardnett ID, Barre PE. The natural history of myocardial disease in dialysis patients. I Am Soc Nephrol 1991, 22:12.
6. Ceballos-Picot I, Witko-Sarast V, Merad-Boudia M, Nguyen T, Thvenin M, Jaudon MC, Zingraff J, Verger C, Junger P, Descamps-Latscha B. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med 1996, 21:845-53.
7. Schmidtmann S, Muller M, von Baehr R, Precht K. Changes of antioxidative homeostasis in patients on chronic haemodialysis. Nephrol Dial Transplant 1991, 6:71-74.
8. Clermont G, Lecourt S, Lahet J, Sohan P, Vergely C, Chevet D, Rifle G, Rochette L. Alteration in plasma antioxidant capacities in chronic renal failure and haemodialysis patients: a possible explanation for the increased cardiovascular risk in these patients. Cardiovasc Res 2000, 47:618-23.
9. Huritz-Swiński R, Mashiah E, Kristal B, Shkolnik T, Shasha SM. Antioxidant enzymes activity in polymorphonuclear leukocytes in chronic renal failure. Nephron 1995, 71:176-79.
10. Chen CK, Liaw JM, Jiang JG, Lin TH. Antioxidant enzymes and trace elements in hemodialyzed patients. Biol Trace Elem Res 1997, 58:149-57.
11. Galli F, Vanga Z, Balla J, Ferraro B, Canestri F, Floridi A, Kakuk G, Buoncristiani U. Vitamin E, lipid profile, and peroxidation in haemodialysis patients. Kidney Int 2001, 59:548-54.
12. Abbey M, Nestel PJ, Baghurst PA. Antioxidant vitamins and low density-lipoprotein oxidation. Am J Clin Nutr 1993, 58:529-32.
13. Hodis HN, Mack WI, LaBree L, Cashin-Hemphill L, Sevanian A, Johnson R, Azen SP. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. JAMA 1995, 273:1849-54.
14. Stampfer MJ, Rimm EB. Epidemiologic evidence for vitamin E in prevention of cardiovascular disease. Am J Clin Nutr 1995, 62:635S-695S.
15. Mohora M, Mirescu G, Cizan C, Mihaliescu I, Gimelea L, Uresea N, Dinu V. Effect of haemodialysis on lipid peroxidation and antioxidant system in patients with chronic renal failure. Rom J Intern Med 1995, 33:37-42.
16. Epler K, Ziegler R, Craft N: Liquid chromatographic method for the determination of carotenoids, retinoids and tocopherols in human serum and in food. J Chromatogr 1993, 619:37-48.

17. Grotch D, Santa Maria LD, Boeira S: Rapid quantification of malondialdehyde in plasma by high performance liquid chromatography-visible detection. J Pharm Biomed Anal 2007, 43:619-24.

18. Garcia SC, Schott K, Charlo M: Quantification of reduced glutathione by HPLC-UV in erythrocytes of haemodialysis patients. Biomed Chromatogr 2008, 22:460-68.

19. McCord JM, Fridovich I: Superoxide dismutase. An enzymic function for erythrocuprein, a copper protein of blood. J Biol Chem 1969, 244:4059-55.

20. Aebi H: Catalase in vitro. Methods Enzymol 1984, 105:121-26.

21. Paglia D, Valentini W: Studies on the quantitative and qualitative characterization or erythrocyte glutathione peroxidase. J Lab Clin Med 1967, 70:158-69.

22. Ha TK, Sattar N, Talwar D, Cooney J, Simpson K, O’Brien S: Increased production of superoxide. J Intern Med 1996, 239:679-83.

23. Lindner A, Charra B, Sherrard DJ, Scribner BH: Oxidized Low Density Lipoproteins in Atherosclerosis. J Biol Chem 1965, 240:1066-75.

24. Reaven PD, Witzum JL: Oxidized Low Density Lipoproteins in Atherosclerosis: Role of Dietary Modification. Annual Review of Nutrition 1996, 16:51-71.

25. Kinosian B, Glick H, Garland G: Cholesterol and Coronary Heart Disease: Predicting Risks by Levels and Ratios. Ann Intern Med 1994, 121:641-47.

26. Valentini J, Grott D, Panz C, Roehrs M, Burg G, Garcia SC: The influence of the haemodialysis treatment time under oxidative stress biomarkers in chronic renal failure patients. Biomed Pharmacother 2006, 62:378-82.

27. Steenvinkel P, Heimmüller D, Paulse F, Diczfalusy U, Wang T, Berglund L, Jogerstrand T: Strong association between malnutrition, inflammation and atherosclerosis in chronic renal failure. Kidney Int 1999, 55:1889-911.

28. Valentini J, Schmitt GC, Grotch D, Maria LDS, Boeira SP, Piva S, Brucker N, Bohrer P, Pomblum VJ, Emanuelli T, Garcia S: Elimination of Hydrogen Peroxide in Erythrocytes. J Pharm Biomed Anal 2007, 41:276-83.

29. Silva AC, Rocha JBT, Monch ALB, Zanin RF, Kaier R, Maldonato PA, Arantes LC, Silva LA, Morsch VM, Schetinger MRC: Oxidative stress and d-ALA-D activity in chronic renal failure patients. Biomed Pharmacother 2007, 61:180-85.

30. Schiavon R, Biasioli S, De Fanti E, Petrosino L, Cavallini L, Cavalcanti G, Bohrer D, Pomblum VJ, Emanuelli T, Garcia S: Aminolevulinate dehydratase activity and oxidative stress in chronic renal failure patients. Biomed Pharmacother 1999, 53:591-94.

31. Cohen G, Hochstein P: Glutathione Peroxidase: The Primary Agent for the Elimination of Hydrogen Peroxide in Erythrocytes. Biochem 1963, 2:1420-29.

32. Roehrs M, Valentini J, Bulcão R, Moreira JC, Biesalski H, Limberger R, Arantes LC, Silva LA, Morsch VM, Schetinger MRC: The plasma glutathione peroxidase enzyme in hemodialyzed subjects. J Appl Clin Lab Med 2009, 4:233-27.

33. Bhogade RB, Suryakar AN, Joshi NG, Patil RY: Effect of vitamin E supplementation on oxidative stress in hemodialysis patients. Indian J Clin Biochem 2008, 23:233-237.

34. Winklhofer-Roob BM, Rock E, Ribalta J, Shemerling DH, Roob JM: Effects of vitamin E and carotenoid status on oxidative stress in health and disease. Evidence obtained from human intervention studies. Mol Aspects Med 2003, 24:391-402.

35. Kaysen GA: ACAT inhibition reverses LCAT deficiency and decreases plasma cholesterol in humans. J Clin Invest 1996, 97:158-69.

36. Vaziri ND, Liang K: Deficiencies of antioxidant vitamin and carotenoid status in chronic renal failure. QJM 1996, 89:765-69.

37. Cominacini L, Rigoni A, Pasini AF, et al: The binding of oxidized low density lipoprotein (ox-LDL) to ox-LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide. J Biol Chem 2001, 276:13750-5.

38. Fossella C, Olivo C, Rizzuti G, Nediani C, Pacini A, Nasi P: Oxidative stress and antioxidant defenses in renal patients receiving regular hemodialysis. Clin Chem Lab Med 1998, 36:149-53.

39. Montazerifar F, Hashemi M, Karajibani M, Dikshit M: Hemodialysis Alters Lipid Profiles, Total Antioxidant Capacity, and Vitamins A, E, and C Concentrations in Humans. J Med Food 2010, 13(6):1490-1499.

40. Bhogade RB, Suryakar AN, Joshi NG, Patil RY: Effect of vitamin E supplementation on oxidative stress in hemodialysis patients. Indian J Clin Biochem 2008, 23:233-237.

41. Winklhofer-Roob BM, Rock E, Ribalta J, Shemerling DH, Roob JM: Effects of vitamin E and carotenoid status on oxidative stress in health and disease. Evidence obtained from human intervention studies. Mol Aspects Med 2003, 24:391-402.

42. Young IS, Woodside JV: Antioxidants in health and disease. J Clin Pathol 2001, 54:176-186.

43. Gray B, Kan E, Bali M, Hincal F, Basaran N: The effect of vitamin E supplementation on antioxidant enzyme activities and lipid peroxidation levels in hemodialysis patients. Clin Chim Acta 2003, 338:91-98.

44. Bonnefont-Rousselot D, Jaudon MC, Isaad B, Cacoub P, Congy F, Jardel C, et al: Antioxidant status of elderly chronic renal patients treated by continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1997, 12:1399-405.

45. Boeschoten EW, Srivjer J, Krediet RT, Schreurs WHP, Arisz L: Deficiencies of vitamins in CAPD patients: the effect of supplementation. Nephrol Dial Transplant 1988, 2:87-93.

46. Sattler W, Christison J, Stocker R: Cholesterolester hydroperoxide reducing activity associated with isolated high density and low density lipoproteins. Free Radic Biol Med 1995, 18:421-29.

47. Tapiero H, Townsend DM, Tew KD: The role of carotenoids in the prevention of human pathologies. Biomed Pharmacother 2004, 58:100-10.

48. Rock CL, Jahnke MG, Gorenflo DW, Swartz RD, Messana JM: Racial group differences in plasma concentrations of antioxidant vitamins and carotenoids in haemodialysis patients. Am J Clin Nutr 1997, 65:844-50.

49. Mackness MI, Abbott C, Durngton PN, Am J: The role of high density lipoprotein in lipid-soluble antioxidant vitamins in inhibiting low density lipoprotein oxidation. Biochem J 1993, 294:629-34.

50. Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, Valente AJ, Berliner JA, Drinkwater DC, Laks H, Fogelman AM: Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic-wall cells is due to induction of monocyte chemotactic protein-1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991, 88:2039-46.

51. Sundl I, Roob JM, Meinitzer A, Tian B, Khoschosorur G, Haditsch B, Holzer H, Winklhofer-Roob BM: Antioxidant Status of patients on peritoneal dialysis: associations with inflammation and glycoxidative stress. Peritoneal Dialysis International 2009, 29:69-101.

52. Drougey CM, Young IS, McEneny J, McDowell F, McMastor C, Ncmie D, Trimble ER: Oxidation of low density lipoprotein in patients on regular haemodialysis. Atherosclerosis 1994, 110:89-93.

53. Rissanen T, Vuillitainen S, Nyyssonen K, Salonen JT, Lycopene, Atherosclerosis, and Coronary Heart Disease. Exper Biol Med 2002, 227:907-9.

54. To Y, Oscha J, Sasaki R, Suzuki S, Kasahara Y, Morimitu Y, et al: Serum concentrations of carotenoids, retinol, and a-tocopherol in healthy persons determined by high performance liquid chromatography. Clin Chim Acta 1990, 194:131-44.

55. Olmedilla B, Granado F, Gil-Martinez E, Blanco I, Rojas-Hidalgo E: Effects of retinol, tocopherol, and main carotenoids in serum of control and insulindependent diabetic Spanish subjects. Clinical Chemistry 1997, 43(6):1066-1071.

56. Fernández-Banãres F, Giné JJ, Cabré E, Abad-Lacruz A, Esteve-Comas M, Reilly DS, Lean ME: Antioxidant status of elderly chronic renal patients treated by haemodialysis. BMC Nephrology 2011, 12:59.